EA201491276A1 - Новые производные бензилсульфонамида, подходящие для применения в качестве ингибиторов mogat-2 - Google Patents

Новые производные бензилсульфонамида, подходящие для применения в качестве ингибиторов mogat-2

Info

Publication number
EA201491276A1
EA201491276A1 EA201491276A EA201491276A EA201491276A1 EA 201491276 A1 EA201491276 A1 EA 201491276A1 EA 201491276 A EA201491276 A EA 201491276A EA 201491276 A EA201491276 A EA 201491276A EA 201491276 A1 EA201491276 A1 EA 201491276A1
Authority
EA
Eurasian Patent Office
Prior art keywords
benzilsulphonamide
mogat
inhibitors
new
derivatives suitable
Prior art date
Application number
EA201491276A
Other languages
English (en)
Inventor
Мария Кармен Фернандес
Мария Росарио Гонсалес-Гарсиа
Ланс Аллен Пфайфер
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47148691&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201491276(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA201491276A1 publication Critical patent/EA201491276A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/05—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5

Abstract

В настоящем изобретении предложены соединения нижеприведенной формулыи аналоги указанных соединений, для которых различные заместители, R1, R2, R3, R4, R5 А и X, описаны в настоящей заявке, или фармацевтические соли указанных соединений, способ лечения состояния, такого как гипертриглицеридемия, и способ получения соединений.
EA201491276A 2012-01-31 2013-01-24 Новые производные бензилсульфонамида, подходящие для применения в качестве ингибиторов mogat-2 EA201491276A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261592717P 2012-01-31 2012-01-31
EP12382432 2012-11-06
PCT/US2013/022870 WO2013116075A1 (en) 2012-01-31 2013-01-24 Benzyl sulfonamide derivatives useful as mogat - 2 inhibitors

Publications (1)

Publication Number Publication Date
EA201491276A1 true EA201491276A1 (ru) 2014-10-30

Family

ID=47148691

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201491276A EA201491276A1 (ru) 2012-01-31 2013-01-24 Новые производные бензилсульфонамида, подходящие для применения в качестве ингибиторов mogat-2

Country Status (27)

Country Link
US (1) US8575352B2 (ru)
EP (1) EP2809651B1 (ru)
JP (1) JP2015511232A (ru)
KR (1) KR20140106750A (ru)
CN (1) CN104066719B (ru)
AP (1) AP2014007794A0 (ru)
AR (1) AR089771A1 (ru)
AU (1) AU2013215468A1 (ru)
BR (1) BR112014018636A8 (ru)
CA (1) CA2859995A1 (ru)
CL (1) CL2014001861A1 (ru)
CO (1) CO7010839A2 (ru)
CR (1) CR20140322A (ru)
DO (1) DOP2014000178A (ru)
EA (1) EA201491276A1 (ru)
ES (1) ES2590929T3 (ru)
GT (1) GT201400167A (ru)
HK (1) HK1199025A1 (ru)
IL (1) IL233712A0 (ru)
MA (1) MA35886B1 (ru)
MX (1) MX2014008599A (ru)
PE (1) PE20141679A1 (ru)
PH (1) PH12014501711A1 (ru)
SG (1) SG11201404106QA (ru)
TW (1) TW201343629A (ru)
WO (1) WO2013116075A1 (ru)
ZA (1) ZA201404836B (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013112323A1 (en) 2012-01-23 2013-08-01 Eli Lilly And Company Phenyl methanesulfonamide derivatives useful as mgat - 2 inhibitors
CN104080777B (zh) 2012-01-31 2015-12-09 伊莱利利公司 用作mogat-2抑制剂的吗啉基衍生物
EA201590696A1 (ru) 2012-11-06 2015-08-31 Эли Лилли Энд Компани Новые бензилсульфонамидные соединения, подходящие в качестве ингибиторов mogat-2
CN107820425B (zh) 2015-06-15 2021-08-31 Nmd制药股份公司 用于治疗神经肌肉病症的化合物
TWI782056B (zh) 2017-07-14 2022-11-01 日商鹽野義製藥股份有限公司 具有ｍｇａｔ２抑制活性的縮合環衍生物
US11591284B2 (en) 2017-12-14 2023-02-28 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US11147788B2 (en) 2017-12-14 2021-10-19 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US10385028B2 (en) 2017-12-14 2019-08-20 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US11730714B2 (en) 2017-12-14 2023-08-22 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
MX2021008050A (es) 2019-01-11 2021-08-05 Shionogi & Co Derivado de dihidropirazolopirazinona que tiene actividad inhibidora de monoacilglicerol aciltransferasa 2 (mgat2).

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1655283A1 (en) * 2004-11-08 2006-05-10 Evotec OAI AG 11beta-HSD1 Inhibitors
EP1659113A1 (en) * 2004-11-08 2006-05-24 Evotec AG Inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 (11beta-HSD1)
CN101087771A (zh) * 2004-11-10 2007-12-12 辉瑞大药厂 经取代n－磺酰基氨基苄基－2－苯氧基乙酰胺化合物
KR20070085957A (ko) * 2004-11-10 2007-08-27 화이자 인코포레이티드 치환된 ｎ-설폰일아미노벤질-2-페녹시 아세트아마이드화합물
WO2008032156A1 (en) * 2006-09-08 2008-03-20 Pfizer Products Inc. Diaryl ether derivatives and uses thereof
WO2008038768A1 (fr) * 2006-09-28 2008-04-03 Dainippon Sumitomo Pharma Co., Ltd. Composé ayant une structure de pyrimidine bicyclique et composition pharmaceutique comprenant le composé
JP2010509392A (ja) * 2006-11-13 2010-03-25 ファイザー・プロダクツ・インク ジアリール、ジピリジニルおよびアリール−ピリジニル誘導体ならびにその使用
WO2009086303A2 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2010095767A1 (en) * 2009-02-23 2010-08-26 Banyu Pharmaceutical Co.,Ltd. Pyrimidin-4(3h)-one derivatives
WO2013112323A1 (en) 2012-01-23 2013-08-01 Eli Lilly And Company Phenyl methanesulfonamide derivatives useful as mgat - 2 inhibitors
CN104080777B (zh) 2012-01-31 2015-12-09 伊莱利利公司 用作mogat-2抑制剂的吗啉基衍生物

Also Published As

Publication number Publication date
DOP2014000178A (es) 2014-08-31
SG11201404106QA (en) 2014-08-28
PE20141679A1 (es) 2014-11-08
ZA201404836B (en) 2017-08-30
BR112014018636A2 (ru) 2017-06-20
TW201343629A (zh) 2013-11-01
EP2809651B1 (en) 2016-06-29
BR112014018636A8 (pt) 2017-07-11
CA2859995A1 (en) 2013-08-08
CO7010839A2 (es) 2014-07-31
CN104066719A (zh) 2014-09-24
ES2590929T3 (es) 2016-11-24
MA35886B1 (fr) 2014-12-01
AR089771A1 (es) 2014-09-17
CR20140322A (es) 2014-08-25
WO2013116075A1 (en) 2013-08-08
JP2015511232A (ja) 2015-04-16
HK1199025A1 (en) 2015-06-19
IL233712A0 (en) 2014-09-30
KR20140106750A (ko) 2014-09-03
GT201400167A (es) 2015-05-28
CN104066719B (zh) 2016-08-24
EP2809651A1 (en) 2014-12-10
MX2014008599A (es) 2014-08-22
US8575352B2 (en) 2013-11-05
CL2014001861A1 (es) 2014-11-07
AU2013215468A1 (en) 2014-07-10
US20130197039A1 (en) 2013-08-01
AP2014007794A0 (en) 2014-07-31
PH12014501711A1 (en) 2014-10-13

Similar Documents

Publication Publication Date Title
EA201491276A1 (ru) Новые производные бензилсульфонамида, подходящие для применения в качестве ингибиторов mogat-2
EA201792535A1 (ru) Гетероциклические амиды в качестве ингибиторов киназ
EA201591455A1 (ru) Производные бензимидазолона в качестве ингибиторов бромодомена
EA201890308A1 (ru) Замещенные азасоединения как ингибиторы irak-4
EA201691085A1 (ru) Замещенные бензамиды и способы их применения
EA201890899A1 (ru) Модуляторы фарнезоидного x-рецептора
EA201400412A1 (ru) ЗАМЕЩЕННЫЕ БЕНЗИЛИНДАЗОЛЫ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Bub1 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ
EA201692079A1 (ru) Ингибиторы лизин-специфической деметилазы-1
EA201790407A1 (ru) Зонды для визуализации белка хантингтина
EA201401292A2 (ru) Новые тиенопиримидиновые производные, способ их получения и фармацевтические композиции, содержащие их
EA201690598A1 (ru) Аминогетероарил бензамиды в качестве ингибиторов киназы
EA201690952A1 (ru) Пиразол для лечения аутоиммунных расстройств
EA201591634A1 (ru) Дигидропиридопиримидиновые соединения
EA201692114A1 (ru) Замещенные дигидроизохинолиноновые соединения
EA201790599A1 (ru) Соединения и композиции в качестве ингибиторов киназ
EA201490474A1 (ru) Аминохиназолины в качестве ингибиторов киназ
EA201890331A1 (ru) Пиридинондикарбоксамиды для применения в качестве ингибиторов бромодомена
EA201591360A1 (ru) Азабензимидазолы в качестве ингибиторов изозимов фдэ4 для лечения цнс и других расстройств
EA201690764A1 (ru) Ингибитор грелин-o-ацилтрансферазы
EA201690844A1 (ru) Ингибиторы gsk-3
EA201592183A1 (ru) Ингибиторы bace
EA201590552A1 (ru) Аминохинолины в качестве ингибиторов киназы
EA201790400A1 (ru) Зонды для визуализации белка хантингтина
DOP2014000177A (es) Nuevos derivados de morofolinilo útiles como inhibidores de mogat-2
EA201690523A1 (ru) Триазолопиридины, композиции и способы их применения